Other Events ·
Tyra Biosciences announced initial results from its Phase 2 SURF302 study of oral dabogratinib in FGFR3-altered…
TYRATyra Biosciences, Inc.
Tyra Biosciences announced initial results from its Phase 2 SURF302 study of oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. The data identified a 60 mg once-daily dose as optimal for the planned adjuvant strategy, showing an overall response rate of 79% and a complete response rate of 57% at three months with favorable safety profiles. The company plans to engage health authorities on Phase 3 design and initiate a registrational study in 2027. Additionally, Tyra reported a complete response in the first patient of its SURF303 trial for upper tract urothelial cancer and cleared the fifth dose level in its pediatric achondroplasia study BEACH301 without safety signals. The company operates in the biotechnology industry, developing targeted therapies for oncology and rare diseases.